ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-CCP"

  • Abstract Number: 1741 • ACR Convergence 2023

    The Occurrence and Phenotype of Autoreactive T Cells in the At-Risk Phase of Rheumatoid Arthritis

    Sara Turcinov1, Charlotte de Vries2, Ravi Kumar Sharma2, Christina Gerstner2, Bruno Raposo2, Anatoly Dubnovitsky2, William Kwok3, Karine Chemin2, Vivianne Malmström4 and Aase Hensvold5, 1Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet. Theme of Inflammation and Ageing, Medical Unit Gastro, Derma, Rheuma, Karolinska University Hospital, Stockholm, Sweden, 2Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 3Benaroya Research Institute at Virginia Mason, Seattle, WA, 4Karolinska Institutet, Stockholm, Sweden, 5Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet. Center for Rheumatology, Academic Specialist Center, Stockholm, Sweden

    Background/Purpose: CD4+ T cells recognizing citrullinated epitopes are present in peripheral blood of anti-citrulline protein antibody (ACPA) positive rheumatoid arthritis (RA) patients at time of…
  • Abstract Number: 1746 • ACR Convergence 2023

    Smoking as a Risk Factor for Rheumatoid Arthritis: Exclusive Association with IgA Autoantibodies

    Tineke van Wesemael1, Anna Svärd2, Annemarie Dorjee1, Thomas Huizinga1, René Toes1 and Diane van der Woude1, 1Leiden University Medical Center, Leiden, Netherlands, 2Centre for Clinical Research Dalarna, Uppsala, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies to anti-modified protein autoantibodies (AMPAs) like anti-citrullinated protein antibodies (ACPA) and anti-acetylated protein antibodies (AAPA). Smoking is…
  • Abstract Number: 1763 • ACR Convergence 2023

    Asthma Severity Is Associated Increased Serum Anti-cyclic Antibody Level at Baseline and in Increase During Longitudinal Follow-up

    Drayton Rorah1, Linh Ngo2, Mario Castro2, Kristen Demoruelle3 and Scott Matson4, 1University of Kansas Medical Center, Kansas City, KS, 2University of Kansas School of Medicine, Kansas City, KS, 3University of Colorado Anschutz Medical Campus, Aurora, CO, 4University of Kansas School of Medicine, Kansas City, MO

    Background/Purpose: The lung airways have been implicated in the pathogenesis of RA. RA-associated autoantibodies, including anti-cyclic citrullinated peptide (anti-CCP) antibodies are found to be generated…
  • Abstract Number: 1764 • ACR Convergence 2023

    Antibody Responses to Citrullinated Type II Collagen and Vimentin Modified with Malondialdehyde-Acetaldehyde Differ in Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease

    Breanna Butler1, Jill Poole1, Michael Duryee1, Nozima Aripova1, Carlos Hunter1, Bridget Kramer1, James O'Dell1, Geoffrey Thiele1, Bryant England1 and Ted R Mikuls2, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Interstitial lung disease (ILD) causes significant complications and mortality in patients with rheumatoid arthritis (RA). We have previously shown that patients with RA-ILD had…
  • Abstract Number: 1768 • ACR Convergence 2023

    The Dynamics of the Gut Microbiome in Rheumatoid Arthritis Susceptibility: A Cross-Sectional and Longitudinal Observational Study

    Christopher Rooney1, Ian Jeffery2, Kulveer Mankia3, Mark Wilcox1 and Paul Emery4, 1University of Leeds, Leeds, United Kingdom, 24D Pharma plc, Cork, Ireland, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Multiple compositional shifts of gut microbiota have been identified within the rheumatoid arthritis (RA) disease continuum, encompassing both established RA and at-risk individuals (including…
  • Abstract Number: 2121 • ACR Convergence 2023

    Clinical Significance of Negative Seroconversion of Anti-CCP and Anti-Mutated Citrullinated Vimentin Antibodies in Patients with Rheumatoid Arthritis

    Takao Fujii, Katsunori Tanaka, Ryo Matsumiya, Kayoko Tabata and Shigeru Iwata, Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan

    Background/Purpose: Anti-cyclic citrullinated peptide antibody (anti-CCP Ab) positivity is closely associated with bone destruction in rheumatoid arthritis (RA) patients, but the correlation between the Ab…
  • Abstract Number: 2141 • ACR Convergence 2023

    Glucocorticoid Treatment in Early Rheumatoid Arthritis Is Associated with Increased Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Levels: A Post-hoc Analysis of a Randomized Controlled Trial (NORD-STAR)

    Kristina Lend1, Jos W.R. Twisk2, Nupur Kumar3, John Lampa4, Anna Rudin5, Merete Hetland6, Till Uhlig7, Dan Nordstrom8, Mikkel Østergaard9, Marte Schrumpf Heiberg10, Espen A Haavardsholm10, Bjorn Gudbjornsson11, Tuulikki Sokka-Isler12, Gerdur Maria Grondal13, Kim Hørslev-Petersen14, Michael Nurmohamed2, Ronald van Vollenhoven2 and Johan Frostegård3, 1Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Karolinska Institutet, Stockholm, Sweden, 4Stockholm County, Hãsselby, Sweden, 5Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 6Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, 7Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 8Helsinki University Hospital, Helsinki, Finland, 9Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, 10Diakonhjemmet Hospital, Oslo, Norway, 11Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, 12Jyvaskyla Central Hospital, Jyväskylä, Finland, 13Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, 14University of Southern Denmark, Odense, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is associated with an elevated risk for developing atherosclerotic cardiovascular disease (CVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key…
  • Abstract Number: 2431 • ACR Convergence 2023

    Integrated Single Cell Multi-omics Analysis in At-Risk for Future Rheumatoid Arthritis (RA) and Early RA Reveals Shared Transcription Factor Profiles in Multiple Cell Lineages

    Cong Liu1, David Boyle1, Adam Savage2, Marie Feser3, Kristen Demoruelle3, kristine Kuhn4, Michael Holer3, kevin Deane3, Palak Genge2, Morgan Weiss2, Veronica Hernandez2, Julian Reading2, Jane Buckner5, Tom Bumol2, Mark Gillespie2, Peter Skene2, Wei Wang6 and Gary Firestein1, 1University of California San Diego, San Diego, CA, 2Allen Institute for Immunology, Seattle, WA, 3University of Colorado Anschutz Medical Campus, Aurora, CO, 4University of Colorado School of Medicine, Aurora, CO, 5Benaroya Research Institute at Virginia Mason, Seattle, WA, 6University of California San Diego, La Jolla, CA

    Background/Purpose: Identifying molecular signatures associated with anti-citrullinated protein antibody (ACPA) positive individuals who are 'at-risk' for future RA (At-Risk) and early RA (ERA) requires comprehensive…
  • Abstract Number: 0081 • ACR Convergence 2023

    RA Disease Activity Influence the Frequency and Phenotype of Citrulline Reactive CD4 T Cells in DRB1*04:04 ACPA+ RA Patients

    Cliff Rims1, Anne Hocking1, Sylvia Posso1, Bernard Ng2, Jeffrey Carlin3, Jane Buckner4 and Eddie James4, 1Benaroya Research Institute, Seattle, WA, 2Veteran Affairs, Seattle, WA, 3Virginia Mason Medical Center, Seattle, WA, 4Benaroya Research Institute at Virginia Mason, Seattle, WA

    Background/Purpose: The presence of ACPA in RA signifies an immune response toward citrullinated auto-antigens in disease pathogenesis and persistence. RA is a T cell mediated…
  • Abstract Number: 2582 • ACR Convergence 2023

    Expansion of Circulating HLA-DR+ Peripheral Helper T Cells and CXCR5−CD38+ Mature Naïve B Cells in ACPA-positive Individuals At-risk for and with Classified RA

    Hideto Takada1, Kristen Demoruelle1, Kevin Deane1, Shohei Nakamura2, Yasuhiro Katsumata3, Katsunori Ikari2, Jane Buckner4, William H. Robinson5, Jennifer Seifert1, Marie Feser1, LauraKay Moss1, Jill Norri6, Masayoshi Harigai3, Elena Hsieh1, Michael Holer1 and Yuko Okamoto2, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 3Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, 4Benaroya Research Institute at Virginia Mason, Seattle, WA, 5Stanford University, Palo Alto, CA, 6Colorado School of Public Health, Denver, CO

    Background/Purpose: Production of ACPA following T and B cell interactions is a hallmark of ACPA+ RA. Recently identified peripheral helper T (Tph) cells have B…
  • Abstract Number: 0281 • ACR Convergence 2023

    Is There a Decreased Risk of Developing CF Arthropathy in CF Patients Undergoing Treatment That Targets the F508del Mutation?

    Kristin Schmiedeberg1, Anna-Lena Walter1, Lukas Joos1, Martin Brutsche1, Johannes von Kempis2 and Andrea Rubbert-Roth1, 1Cantonal Hospital St. Gallen, St. Gallen, Switzerland, 2Kantonsspital St. Gallen, Division of rheumatology and immunology, St. Gallen, Switzerland

    Background/Purpose: Cystic fibrosis (CF) is characterized by mutations within the CFTR (cystic fibrosis transmembrane conductance regulator) gene that result in a defect of the chloride…
  • Abstract Number: 0389 • ACR Convergence 2023

    The Role of anti-CCP3 Antibodies in anti-CCP2 Antibody Negative Patients with Musculoskeletal Symptoms

    Andrea Di Matteo1, Kulveer Mankia2, Leticia Garcia-Montoya2, Jacqueline Nam2, Sana sharrack3, Michael Mahler4 and Paul Emery3, 1Polytechnic University of Marche, Jesi, Italy, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 4Werfen, San Diego, CA

    Background/Purpose: To investigate, in primary care, whether testing anti-CCP3 antibodies in anti-CCP2 negative individuals with musculoskeletal (MSK) symptoms, improved the prediction of inflammatory arthritis (IA)/rheumatoid…
  • Abstract Number: 0392 • ACR Convergence 2023

    Novel Diagnostic Markers for Rheumatoid Arthritis Including Anti-CarP (Carbamylated Protein), Anti-Sa (Citrullinated Vimentin) and Anti-CEP1 (Citrullinated Enolase Peptide1) Are Frequently Positive in Diagnostic Profiles

    Jane Yang1, Rubio Punzalan1, Lehrhoff Andrew1, Michael Nappi1, Vincent ricchiuti2, Michael Zikry1 and Kelly Chun1, 1Labcorp, Calabasas, CA, 2Labcorp, Dublin, OH

    Background/Purpose: Despite the diagnostic contribution of Anti-CCP3.1 (cyclic citrillunated peptide) antibody and RF (rheumatoid factor) as classified by the 2010 ACR/EULAR RA criteria, approximately one-third…
  • Abstract Number: 0835 • ACR Convergence 2023

    Abatacept in Individuals at Risk of Developing Rheumatoid Arthritis: Results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept (APIPPRA) Trial

    Andrew Cope1, Marianna Jasenecova2, Joana Vasconcelos3, Andrew Filer4, Karim Raza5, Sumera Qureshi2, Maria Antonietta D'Agostino6, Iain McInnes7, John Isaacs8, Arthur Pratt9, Benjamin A Fisher4, Christopher Buckley10, Paul Emery11, Pauline Ho12, Maya Buch13, Coziana Ciurtin14, René Toes15, Thomas Huizinga15, Dirkjan van Schaardenburg16, Caroline Caroline17 and Toby Prevost3, 1King's College London, London, United Kingdom, 2Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 3Nightingale-Saunders Clinical Trials & Epidemiology Unit, King's College London, London, United Kingdom, 4University of Birmingham, Birmingham, United Kingdom, 5Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 6Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, 7University of Glasgow, Glasgow, United Kingdom, 8Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, 9Translational & Clinical Research Institute, University of Newcastle, Newcastle, United Kingdom, 10University of Oxford, Oxford, United Kingdom, 11Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 12Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 13University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, 14Centre for Rheumatology Research, University College London, London, United Kingdom, 15Leiden University Medical Center, Leiden, Netherlands, 16Reade, Amsterdam, Netherlands, 17King's Clinical Trials Unit, King's College London, London, United Kingdom

    Background/Purpose: The definition of higher risk states for rheumatoid arthritis (RA) has been refined in more recent years through inclusion of serum autoantibodies and symptom…
  • Abstract Number: 0533 • ACR Convergence 2022

    Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity

    Timothy Wilson1, Jacob Welch2, Marie Feser2, Elizabeth Bemis2, Claudia Lugo2, Gary S. Firestein3, Thomas F. Bumol4, Jill Norris5, V. Michael Holers6, Kevin D Deane7 and Kristen Demoruelle2, 1University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of California, San Diego, San Diego, CA, 4Allen Institute for Immunology, Seattle, WA, 5Colorado School of Public Health, Aurora, CO, 6University of Colorado, Denver, CO, 7University of Colorado Denver Anschutz Medical Campus, Denver, CO

    Background/Purpose: Presence of systemic anti-CCP-IgG antibodies in individuals without inflammatory arthritis (IA) strongly predicts developing future classified RA. However, published data also demonstrate that 50-70%…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology